This phase I/II trial is evaluating the effectiveness and appropriate dosing for using a combination of two targeted therapies (Durvalumab and Monalizumab) to treat selected advanced solid tumours. In addition, this trial will assess the effectiveness of using the current standard of care therapy, with or without biological agent, in combination with durvalumab and monalizumab or monualizumab alone with biological agent to treat patients with recurrent or metastatic colorectal cancer..
This trial is treating patients with advanced solid tumours.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.